Hikma remains a constituent

Press Release Responsibility 15 August 2023

Hikma remains a constituent of the FTSE4Good Index

London, 15 August 2023 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it remains a constituent of the FTSE4Good Index Series, affirming its strong environmental, social and governance practices.

The FTSE4Good Index Series was created by the global index and data provider FTSE Russell to highlight companies that demonstrate good sustainability practices and to support investors that wish to align their portfolios with such organisations.

Hikma has been a member of the FTSE4Good Index since 2014. Over this time, Hikma has taken substantial steps forward in integrating sustainability into its corporate strategy and strengthening how it manages key themes including minimising environmental impact, expanding access to medicine and promoting an inclusive and empowering workplace.

Susan Ringdal, EVP, Strategic Planning and Global Affairs for Hikma said, “We are pleased to remain constituents of the FTSE4Good and are proud of the steps we continue to take to act responsibly. Promoting more sustainable business practices remains fundamental to our continued success as an organisation and aligns with our purpose of putting better health withing reach, every day.”

For more information on how Hikma acts responsibly, including details of the targets Hikma has set, visit the website or read the Hikma Sustainability Report 2022.

Download press release

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.